Relationship between Inflammatory cytokines and bone mineral density in posmenopausal women with hormone replacement therapy.

Abstract

IntroductionBone formation and resorption are influenced by hormonal and inflammatory processes. Osteoporosis is a systemic disease condition with low bone mineral density (BMD), deterioration of the skeletal micro architecture and increased bone fragility highly prevalent at menopausal women.AimWe evaluated the relationships among inflammatory markers, hormone replacement therapy (E2) and bone mineral density (BMD) in healthy postmenopausal women and determined the contribution of inflammatory markers in BMD after 1‐year hormone replacement.Materials and MethodsThis preliminary analysis included 9 women evaluated pre and 1‐year pos E2 replacement. lumbar spine (LS) BMD were measured by dual energy x‐ray absorptiometry (DEXA) and serum inflammatory markers interleukin (IL)‐8, IL‐ 1β, IL‐6, IL‐10, IL‐12 and tumor necrosis factor‐alpha (TNF‐α) were measured at baseline and 1‐year post E2 replacement by flow cytometry using the Human Inflammation Kit BD Cytometric Bead Array (CBA). Statistical significance was analyzed by SPSS software and p<0.05 was considered statistically significant.ResultsThe Peason correlation analysis showed a significant negative correlation between IL‐1 β and BMD at baseline (r=− 0.803;p=0.009) and 1‐year (r=−0.768;p=0.016).ConclusionsIL‐ 1β is known for its role as inflammation mediator and recent researchers has shown involvement with ovarian processes. Our results suggest that increases in IL‐1β levels are related to decrease in BMD. Thun, modifying inflammatory markers, even in healthy postmenopausal women, may possibly reduce bone loss.